TherapyPhase 2/3NCT02455609
Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain
A Phase 2/3 study testing intrathecal drug administration, Dexmedetomidine and ketamine in people with Therapy and Pain Management, run by Assiut University.
Trial summary
Currently, opioids are widely used for pain relief, but they often provide sub-optimal analgesia with occasional serious side effects. Preservative-free ketamine hydrochloride was introduced as a spinal anesthetic more than twenty years ago and found to have advantages over local anesthetics. Read more about this study
- Who is it for?
- Ages 30 to 50 years
- Conditions the study is for
- Therapy, Pain Management
- What is being tested?
- intrathecal drug administration, Dexmedetomidine and ketamine
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- No sites listed yet
- Study dates
- Mar 2015to Sep 2015
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Aged 30-50 years
- American Society of Anesthesia (ASA) I-II patients
- scheduled for major abdominal cancer surgery
Who cannot join
- known allergy to the study drugs.
- significant cardiac, respiratory, renal or hepatic disease
- coagulation disorder
- infection at the site of intrathecal injection
- drug or alcohol abuse
- BMI > 30 kg/m2
- psychiatric illnesses that would interfere with perception and assessment of pain
About this study
Official title: Intrathecally Administered Ketamine, Dexmedetomidine, and Their Combination With Bupivacaine for Postoperative Analgesia in Major Abdominal Cancer Surgery
Currently, opioids are widely used for pain relief, but they often provide sub-optimal analgesia with occasional serious side effects. Preservative-free ketamine hydrochloride was introduced as a spinal anesthetic more than twenty years ago and found to have advantages over local anesthetics. Intrathecal dexmedetomidine provides an analgesic effect in postoperative pain without severe sedation. The objectives of this study were to compare the efficacy and safety of intrathecally administered dexmedetomidine, ketamine, or their combination when added to bupivacaine for postoperative analgesia in major abdominal cancer surgery.
Read the detailed description
This study was approved by the ethics committee of South Egypt Cancer Institute, Assiut University, Assiut, Egypt. After obtaining a written informed consent, 90 American Society of Anesthesia (ASA) I-II patients aged 30-50 years and scheduled for major abdominal cancer surgery were included in the study. Patients with a known allergy to the study drugs, significant cardiac, respiratory, renal or hepatic disease, coagulation disorder, infection at the site of intrathecal injection, drug or alcohol abuse, BMI > 30 kg/m2 , and psychiatric illnesses that would interfere with perception and assessment of pain were excluded from the study.
Preoperatively, patients were taught how to evaluate their own pain intensity using the visual analogue scale (VAS), scored from 0 -10 (where 0 = no pain, and 10 = the worst pain imaginable).
Oral diazepam (5 mg) was taken the night before surgery. Up on arrival at the operative theatre, a 16-gauge catheter was introduced intravenously at the dorsum of the hand; lactated Ringer's solution 10 mg/kg was infused intravenously over 10 min. before initiation of spinal anesthesia. Basic monitoring probes (electrocardiography, non invasive blood pressure, O2 saturation, and temperature) were applied. Patients were placed in the setting position and a 25-gauge Quincke needle was placed in the L2-3 or L3-4 interspaces.
Patients were randomly divided, by selecting sealed envelopes into one of three groups 30 patients each:
- The dexmedetomidine group (group I) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume intrathecally.
- The ketamine group (group II) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
- Dexmedetomidine + Ketamine group (group III) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
Immediately after their intrathecal injection, the patients were placed in the supine position. After successful spinal anesthesia, general anesthesia was induced with fentanyl 1.5-2 µg/kg, propofol 2-3 mg/kg, and lidocaine 1.5 mg/kg. Endotracheal intubation was facilitated by cis-atracurium 0.15 mg/kg. Heart rate, systolic, and diastolic blood pressure were recorded at 5, 10, 20, 30, 60, 120, 180 minutes. Anesthesia and muscle relaxation were maintained by isoflurane 1- 1.5 MAC in 50% oxygen/air mixture and cis-atracurium 0.03 mg/kg bolus given every 30 min. respectively.
At the end of surgery, muscle relaxation was reversed by neostigmine 50 µg/kg and atropine 20 µg/kg. Patients were extubated and transferred to postanesthesia care unit (PACU) and were monitored for vital signs (heart rate, non invasive blood pressure, respiratory rate, and O2 saturation) immediately postoperative and at 2, 4, 6, 12, 18, and 24 hours postoperative.
VAS scores were assessed at the same time points. Rescue analgesia represented by patient-controlled analgesia (PCA) with intravenous morphine with an initial bolus of 0.1 mg/kg once pain was expressed by the patient, or if VAS was 3 or more (VAS ≥ 3) followed by 1 mg boluses with a lockout period of 5 min. The time of first request of analgesia and total analgesic consumption in the first 24 hours postoperatively were recorded.
The patient's level of sedation was assessed at the same time points using a modified Observer's Assessment of alertness/sedation (OAAS) scale (where 6 = agitated, and 0 = doesn't respond to deep stimuls).
The attendant anesthesiologist, the patient-care giver, and the data collection personnel were all blinded to patient assignment to a specific group. Postoperative adverse effects such as nausea, vomiting, hypotension, bradycardia, cardiac arrhythmias were recorded and treated.
Hypotension was defined as a 15% decrease in systolic blood pressure from baseline. Bradycardia was defined as a heart rate slower than 50 beats per minute or a decrease in heart rate of 20% or more from baseline; whichever is lowest. Hypoxia was defined as an oxygen saturation of less than 90%. Hypotension was treated with intravenous boluse of ephidrine 0.1 mg/kg and normal saline 5ml/kg; the same doses were repeated as required. Bradycardia was treated with intravenous atropine 0.01 mg/kg.
- Conditions
- Therapy, Pain Management
- Being tested
- intrathecal drug administration, Dexmedetomidine, ketamine, Bupivacaine
- Keywords
- dexmedetomidine, ketamine, postoperative pain
- Medical subject headings
- Agnosia, Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
intrathecal drug administrationProcedure or surgery
pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
DexmedetomidineDrug
ketamineDrug
BupivacaineDrug
| Study group | Role | What they receive |
|---|---|---|
| dexmedetomidine (I) | Active comparator | intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume. Receives: Procedure: intrathecal drug administration; Drug: Dexmedetomidine; Drug: Bupivacaine |
| ketamine (II) | Active comparator | intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume. Receives: Procedure: intrathecal drug administration; Drug: ketamine; Drug: Bupivacaine |
| Dexmedetomidine + Ketamine group (III) | Active comparator | intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume. Receives: Procedure: intrathecal drug administration; Drug: Dexmedetomidine; Drug: ketamine; Drug: Bupivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analogue Scale (VAS)
efficacy of analgesia
Measured: the first 24 hours postoperative
Secondary outcomes (3)
time to first request of analgesia
time needed by participating patients in each group to ask for rescue analgesia during the first 24 hours postoperative
Measured: the first 24 hours postoperative
total analgesic consumption
total amount of rescue analgesic taken by patients in each group during the first 24 hours postoperative
Measured: the first 24 hours postoperative
side effects
incidence of nausea (no.), vomiting (no.), hypotension (mmHg), bradycardia (b/m), hypertension (mmHg), arrhythmia (no.), sedation (by a 0-4 sedation scale) experienced by participating patients in each group
Measured: the first 24 hours postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2015 (estimated)
- Study startMar 2015
- Primary completionAug 2015 (estimated)
- Study completionSep 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TherapyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmad Mohammad Abd El-Rahman, Assiut University
- Investigators
- Ahmad M Abd El-Rahman, M.D., Principal investigator, South Egypt Cancer Institute, Assiut University, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02455609
- Sponsor's protocol ID
- 210
- Status last verified
- May 2015
- First submitted
- 18 May 2015
- Last updated
- 28 May 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intrathecally Administered Ketamine, Dexmedetomidine, and Their Combination With Bupivacaine for Postoperative Analgesia in Major Abdominal Cancer Surgery
- ClinicalTrials.gov ID
- NCT02455609
- Acronym / sponsor ID
- 210
- Conditions
- Therapy, Pain Management
- Keywords
- dexmedetomidine, ketamine, postoperative pain
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Mar 2015
- Primary completion
- Aug 2015 (estimated)
- Study completion
- Sep 2015 (estimated)
- First posted
- 28 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Currently, opioids are widely used for pain relief, but they often provide sub-optimal analgesia with occasional serious side effects. Preservative-free ketamine hydrochloride was introduced as a spinal anesthetic more than twenty years ago and found to have advantages over local anesthetics. Intrathecal dexmedetomidine provides an analgesic effect in postoperative pain without severe sedation. The objectives of this study were to compare the efficacy and safety of intrathecally administered dexmedetomidine, ketamine, or their combination when added to bupivacaine for postoperative analgesia in major abdominal cancer surgery.
Detailed description
This study was approved by the ethics committee of South Egypt Cancer Institute, Assiut University, Assiut, Egypt. After obtaining a written informed consent, 90 American Society of Anesthesia (ASA) I-II patients aged 30-50 years and scheduled for major abdominal cancer surgery were included in the study. Patients with a known allergy to the study drugs, significant cardiac, respiratory, renal or hepatic disease, coagulation disorder, infection at the site of intrathecal injection, drug or alcohol abuse, BMI > 30 kg/m2 , and psychiatric illnesses that would interfere with perception and assessment of pain were excluded from the study.
Preoperatively, patients were taught how to evaluate their own pain intensity using the visual analogue scale (VAS), scored from 0 -10 (where 0 = no pain, and 10 = the worst pain imaginable).
Oral diazepam (5 mg) was taken the night before surgery. Up on arrival at the operative theatre, a 16-gauge catheter was introduced intravenously at the dorsum of the hand; lactated Ringer's solution 10 mg/kg was infused intravenously over 10 min. before initiation of spinal anesthesia. Basic monitoring probes (electrocardiography, non invasive blood pressure, O2 saturation, and temperature) were applied. Patients were placed in the setting position and a 25-gauge Quincke needle was placed in the L2-3 or L3-4 interspaces.
Patients were randomly divided, by selecting sealed envelopes into one of three groups 30 patients each:
- The dexmedetomidine group (group I) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume intrathecally.
- The ketamine group (group II) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
- Dexmedetomidine + Ketamine group (group III) received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
Immediately after their intrathecal injection, the patients were placed in the supine position. After successful spinal anesthesia, general anesthesia was induced with fentanyl 1.5-2 µg/kg, propofol 2-3 mg/kg, and lidocaine 1.5 mg/kg. Endotracheal intubation was facilitated by cis-atracurium 0.15 mg/kg. Heart rate, systolic, and diastolic blood pressure were recorded at 5, 10, 20, 30, 60, 120, 180 minutes. Anesthesia and muscle relaxation were maintained by isoflurane 1- 1.5 MAC in 50% oxygen/air mixture and cis-atracurium 0.03 mg/kg bolus given every 30 min. respectively.
At the end of surgery, muscle relaxation was reversed by neostigmine 50 µg/kg and atropine 20 µg/kg. Patients were extubated and transferred to postanesthesia care unit (PACU) and were monitored for vital signs (heart rate, non invasive blood pressure, respiratory rate, and O2 saturation) immediately postoperative and at 2, 4, 6, 12, 18, and 24 hours postoperative.
VAS scores were assessed at the same time points. Rescue analgesia represented by patient-controlled analgesia (PCA) with intravenous morphine with an initial bolus of 0.1 mg/kg once pain was expressed by the patient, or if VAS was 3 or more (VAS ≥ 3) followed by 1 mg boluses with a lockout period of 5 min. The time of first request of analgesia and total analgesic consumption in the first 24 hours postoperatively were recorded.
The patient's level of sedation was assessed at the same time points using a modified Observer's Assessment of alertness/sedation (OAAS) scale (where 6 = agitated, and 0 = doesn't respond to deep stimuls).
The attendant anesthesiologist, the patient-care giver, and the data collection personnel were all blinded to patient assignment to a specific group. Postoperative adverse effects such as nausea, vomiting, hypotension, bradycardia, cardiac arrhythmias were recorded and treated.
Hypotension was defined as a 15% decrease in systolic blood pressure from baseline. Bradycardia was defined as a heart rate slower than 50 beats per minute or a decrease in heart rate of 20% or more from baseline; whichever is lowest. Hypoxia was defined as an oxygen saturation of less than 90%. Hypotension was treated with intravenous boluse of ephidrine 0.1 mg/kg and normal saline 5ml/kg; the same doses were repeated as required. Bradycardia was treated with intravenous atropine 0.01 mg/kg.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| dexmedetomidine (I) | Active comparator | Procedure: intrathecal drug administration, Drug: Dexmedetomidine, Drug: Bupivacaineintrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume. |
| ketamine (II) | Active comparator | Procedure: intrathecal drug administration, Drug: ketamine, Drug: Bupivacaineintrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume. |
| Dexmedetomidine + Ketamine group (III) | Active comparator | Procedure: intrathecal drug administration, Drug: Dexmedetomidine, Drug: ketamine, Drug: Bupivacaineintrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume. |
Who may qualify
- Ages
- 30 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Aged 30-50 years
- American Society of Anesthesia (ASA) I-II patients
- scheduled for major abdominal cancer surgery
Key exclusion criteria (7 listed)
- known allergy to the study drugs.
- significant cardiac, respiratory, renal or hepatic disease
- coagulation disorder
- infection at the site of intrathecal injection
- drug or alcohol abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| intrathecal drug administrationpre-emptive intrathecal administration of analgesic medications for control of postoperative pain. | Procedure or surgery | Dexmedetomidine + Ketamine group (III), dexmedetomidine (I), ketamine (II) |
| Dexmedetomidine | Drug | Dexmedetomidine + Ketamine group (III), dexmedetomidine (I) |
| ketamine | Drug | Dexmedetomidine + Ketamine group (III), ketamine (II) |
| Bupivacaine | Drug | Dexmedetomidine + Ketamine group (III), dexmedetomidine (I), ketamine (II) |
Primary outcome
Visual Analogue Scale (VAS)
Time frame: the first 24 hours postoperative
efficacy of analgesia
3 secondary outcomes
time to first request of analgesia
Time frame: the first 24 hours postoperative
total analgesic consumption
Time frame: the first 24 hours postoperative
side effects
Time frame: the first 24 hours postoperative
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2015.
Related trials for Therapy
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmad M Abd El-Rahman, M.D. principal investigator
South Egypt Cancer Institute, Assiut University, Egypt
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing intrathecal drug administration, Dexmedetomidine and ketamine in people with Therapy and Pain Management, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 May 2015. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analogue Scale (VAS) (time frame: the first 24 hours postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2015.